Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of PRS-080#022-DP in anemic chronic kidney disease patients on hemodialysis
2016-004472-21Phase 2Completed
- Sponsor
- Pieris Pharmaceuticals
- Start
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of PRS-080 in anemia of inflammation (AI), chronic kidney disease (CKD) and end-stage kidney disease (ESKD) (2 arms), sponsored by Pieris Pharmaceuticals. Primary endpoints: Safety and tolerability of PRS-080#022-DP, Pharmacokinetics of PRS-080#022-DP and 1 more. Started Jun 2017; status: completed.
02
Drugs
PRS-080
03
Conditions
anemia of inflammation (AI)chronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2016-004472-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004472-21.